Trinity Biotech PLC F-3/A, filed Nov 29, 2024
Trinity Biotech PLC (TRIB)
F-3/A
2024-11-29
View Original
Added on
October 18, 2026
Registration No. 333-283273
As filed with the Securities and Exchange Commission on November 29, 2024
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1
to
FORM F-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
TRINITY BIOTECH PLC
(Exact name of registrant as specified in its charter)
|
Republic of Ireland
(State or other jurisdiction of incorporation or organization) |
Not Applicable
(I.R.S. Employer Identification No.) |
IDA Business Park
Bray, County Wicklow
A98 H5C8
Ireland
+353 1 276 9800
(Address and telephone number of registrant's principal executive offices)
Puglisi & Associates
850 Library Avenue, Suite 204
Newark, Delaware 19711
Tel. (302) 738-6680
(Name, address and telephone number of agent for service)
Copies of all communications, including communications sent to agent for service, should be sent to:
Steven J. Glusband, Esq.
Mary Brown, Esq.
Carter Ledyard & Milburn LLP
28 Liberty Street
New York, New York 10005
(212) 732-3200
David Fitzgibbon, Esq.
David Jones, Esq.
Matheson LLP
70 Sir John Rogerson's Quay
Dublin 2 Ireland
+353 1 232 2000
Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check
the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the
Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional
classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Emerging growth company ☐
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a
further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as
the Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
The sole purpose of this Amendment No. 1 to the Registration Statement on Form F-3 (333-283273) (the “Registration Statement”) is to file Exhibit 4.3 (the “Exhibit”). Accordingly, this Amendment
No. 1 consists only of the facing page, this explanatory note, Part II, including the signature page and exhibit index, and the Exhibit. This Amendment No. 1 does not contain a copy of the prospectus that was included in the Registration Statement
and is not intended to amend or delete any part of the prospectus.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 8. Indemnification of Directors and Officers.
The registrant’s constitution provides that every director and other officer of the registrant (other than an auditor) shall be indemnified out of the assets of the registrant
against any liability incurred by him in defending any proceedings, whether civil or criminal, in relation to his acts while acting in such office in which judgment is given in his favor or in which he is acquitted or in connection with any
application in which relief is granted to him by the court under the Irish Companies Act 2014. We have entered into indemnification agreements with directors and senior management. Each such indemnification agreement provides the director or office
holder with indemnification permitted under applicable law and to the extent that these liabilities are not covered by directors’ and officers’ insurance.
Item 9. Exhibits.
The index to exhibits appears below on the page immediately following the signature pages of this Registration Statement.
Item 10. Undertakings.
(a) The undersigned registrant hereby undertakes:
| (1) |
to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
|
| (i) |
to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933 (the “Securities Act”);
|
| (ii) |
to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
more than a 20% change in the maximum aggregate offering price set forth in the ‘‘Calculation of Registration Fee’’ table in the effective registration statement; and
|
| (iii) |
to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in this Registration Statement;
|
provided, however, that paragraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) that are incorporated by reference in this Registration Statement or
is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement.
| (2) |
that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
|
| (3) |
to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
|
| (4) |
to file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and
information otherwise required by Section 10(a)(3) of the Securities Act of 1933 need not be furnished, provided, that the registrant includes in the prospectus, by means of a post-effective amendment,
financial statements required pursuant to this paragraph (4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the
foregoing, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act of 1933 or Rule 3-19 of Regulation S-X if such financial statements and information are
contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Form F-3.
|
| (5) |
that, for the purpose of determining any liability under the Securities Act to any purchaser:
|
| (i) |
each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be a part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
|
| (ii) |
each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of
providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or
the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed
to be a new effective date of the registration statement relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that
was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
|
| (6) |
that, for the purpose of determining liability of a registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the
undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
|
| (i) |
any preliminary prospectus or prospectus of the undersigned registrant to the offering required to be filed pursuant to Rule 424;
|
| (ii) |
any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned registrant;
|
| (iii) |
the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
|
| (iv) |
any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
II - 2
| (b) |
The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable,
each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the
securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
| (c) |
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions referred to in Item 8, or otherwise, the registrant
has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
|
| (d) |
The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act,
|
| (1) |
the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the
Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective.
|
| (2) |
each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
|
| (e) |
The registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of section 310 of the Trust Indenture Act (“Act”) in accordance with the rules and
regulations prescribed by the Commission under section 305(b)2 of the Act.
|
II - 3
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No. 1 to the
registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Wicklow, Ireland, on November 29, 2024.
|
TRINITY BIOTECH PLC
|
||
|
|
|
|
|
By:
|
/s/ John Gillard
|
|
|
|
John Gillard
|
|
|
|
Chief Executive Officer
|
|
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below on November
29, 2024 by or on behalf of the following persons in the capacities indicated.
|
Signature
|
|
Title
|
|
|
|
|
|
/s/ John Gillard
|
|
Chief Executive Officer (Principal Executive Officer), Company Secretary and Director
|
|
John Gillard
|
|
|
|
|
|
|
|
*
|
|
Chief Financial Officer
|
|
Louise Tallon
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
James Walsh
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
Ronan O’Caoimh
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
Thomas Lindsay
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
Andrew Omidvar
|
|
|
|
|
|
|
|
*By:
|
/s/ John Gillard
|
|
|
Name:
|
John Gillard
|
|
|
Title:
|
Attorney-in-fact
|
|
II - 4
SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized
representative in the United States of the Registrant, has signed this Amendment No. 1 to the registration statement on November 29, 2024.
|
Puglisi & Associates
|
|
|
|
|
|
|
|
By:
|
/s/ Donald J. Puglisi
|
|
|
|
Name: Donald J. Puglisi
|
|
|
|
Title: Managing Director
|
|
II - 5
|
Exhibit No.
|
Description of Exhibit
|
________________
*Previously Filed.
II - 6
Exhibit 4.3
FINANCIAL ADVISORY AGREEMENT
October 10, 2024
Trinity Biotech plc
Dear Louise Tallon:
The purpose of this letter (the “Agreement”) is to confirm the engagement of Craig-Hallum Capital Group LLC (“Advisor”) by Trinity Biotech plc (the “Company”) to render financial
advisory services to the Company.
1. Engagement of Consultant. The Company hereby engages Advisor and Advisor hereby agrees to render services on a non-exclusive basis to the Company as a corporate
finance consultant.
2. Services. During the term of this Agreement, Advisor shall provide advice to, and consult with, the Company concerning business and financial planning,
corporate organization and structure, and private and public equity and debt financing, and such other matters as the parties may mutually agree to with respect to the Company’s financial interests and needs. Such advice and consultation is
hereinafter referred to as “Financial Services”. The Financial Services shall be provided to the Company in such form, manner and place as the parties
mutually agree. Advisor shall not by this Agreement be prevented or barred from rendering services of the same or similar nature, as herein described, or services of any nature whatsoever for, or on behalf of, persons, firms, or corporations other
than the Company. The Company acknowledges that Advisor and its affiliates may have and continue to have investment banking, advisory and other relationships with parties other than the Company pursuant to which Advisor may acquire information of
interest to the Company. Advisor shall have no obligation to disclose such information to the Company, or to use such information in connection with the Financial Services.
3. Term. The term of this Agreement shall be a period commencing on the date of this Agreement and continuing through the earlier of January 31, 2025 or the
completion of an equity offering (the “Offering”) (the “Term”).
4. Compensation. As compensation for the Financial Services, the Company shall pay US$1,124,500 to the Advisor within 5 business days of the date of this letter as
a non-refundable retainer fee (the “Retainer”). The parties further agree that, from the date of this letter until the date on which it is discharged by the
Company, the Retainer is and shall be a liability for a liquidated sum for the purposes of section 64(3)(c) of the Companies Act 2014 of Ireland and for all other purposes.
At the Company’s election, and without any prior notice to, or consent from, the Advisor, the Company may elect to
discharge the Retainer in full by delivering or procuring the delivery of 650,000 American Depository Shares (“ADSs”) of the Company (the ADSs delivered to the
Advisor, the “Shares”) to a DRS account maintained by the depositary for the Shares (the “Depositary”) on behalf of the Advisor.
Advisor represents and warrants that it is an “accredited investor” as defined in Rule 501 of Regulation D
promulgated under the Securities Act. Advisor represents and warrants that it shall acquire the Shares as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of the Shares (this representation is not limiting Advisor’s right to sell the Shares pursuant to an effective registration statement under the Securities Act or otherwise in compliance with applicable federal and state securities
laws). The Advisor understands that issuance of the Shares are not, and may never be, registered under the Securities Act, or the securities laws of any state and, accordingly, the DRS account representing such securities will be subject to a legend
substantially similar to the following:
“THE OFFER AND SALE OF THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.”
The DRS account evidencing the Shares shall not be subject to any legend (including the legend set forth above), (i)
while a registration statement covering the resale of such Shares is effective under the Securities Act, (ii) following any sale of such Shares pursuant to Rule 144 under the Securities Act, (iii) if such Shares have been held for 6 months and are
eligible for sale under Rule 144 or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Securities and Exchange Commission (the “Commission”) and the earliest of clauses (i) through (iv), the “Delegend Date”).
The Company shall cause its counsel to issue a legal opinion to the Depositary promptly after the Delegend Date if required by the Company and/or the Depositary to effect the removal of the legend hereunder, or at the request of the Advisor. The
Company agrees that following the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than one (1) trading day (a day on which the ADSs are traded on the primary national market or exchange
(“Trading Day”) following the date on which the Company has received of a written request from the Advisor (the “Legend Removal Date”) cause the Depositary to
remove any legend from the DRS account maintained on behalf of the Advisor or, at the request of the Advisor, shall credit the account of the Advisor’s prime broker with the Depository Trust Company System as directed by the Advisor. The Advisor
covenants and agrees that, in the event that the Shares are delegended pursuant to clause (iii) above, it shall desist from selling any Shares during any periods that the Company is not then current in its filings under the Securities Exchange Act of
1934, as amended, until such time that the Company is then current in its filiings.
In addition to the Advisor’s other available remedies, the Company shall pay to Advisor, in cash, (i) as partial
liquidated damages and not as a penalty, for each $1,000 of Shares (based on the daily volume weighted average price of the ADSs (“VWAP”) on the date that
notice is submitted to the Depositary) to remove the restrictive legend from the Advisor’s DRS account, $5 per Trading Day (increasing to $10 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after
the Legend Removal Date until such Shares are delivered without a legend and (ii) if the Company fails to (a) cause the Shares in the DRS account maintained on behalf of the Advisor to be transferable free from all restrictive and other legends (and
such failure is not caused by an act or omission of the Advisor) and (b) if after the Legend Removal Date the Advisor purchases (in an open market transaction or otherwise) American Depositary Shares of the Company ( “ADSs”) required to be delivered in satisfaction of a sale by the Advisor of all or any portion of the number of ADSs that the Advisor anticipated receiving from the Company without any
restrictive legend, then, an amount equal to the excess of the Advisor’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the ADSs so purchased (provided, the Advisor exercises reasonable efforts to
minimize the amount of such purchase price) over the product of (A) such number of Shares that the Company was required to deliver to the Advisor by the Legend Removal Date and for which the Advisor was required to purchase shares to timely satisfy
delivery requirements, multiplied by (B) the weighted average price at which the Advisor sold that number of ADSs. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any
Shares.
The Company shall prepare and file with the Commission a registration statement (the “Resale Registration Statement”) relating to the resale of the Shares by the Advisor under the Securities Act on or before the 30th calendar day following the date hereof (the “Filing Date”) and use best efforts to cause such registration statement to be declared effective by the Commission as soon as practical following the date hereof
(and in any event on or before December 15, 2024) (the “Effectiveness Date”). The Company shall use best efforts to maintain effectiveness of the Resale
Registration Statement at all times until the earlier of the date Advisor has sold all of the Shares or the date that the Shares may be sold pursuant to Rule 144 under the Securities Act (the “End Date”). In the event that the Company fails to (i) file the Registration Statement on or before the Filing Date, (ii) have the Registration Statement declared effective by the Commission by the
Effectiveness Date or (iii) maintain the effectiveness of the Resale Registration Statement until the End Date then, in addition to any other rights the Advisor may have hereunder or under applicable law, on the Filing Date or the Effectiveness
Date, if the Registration Statement has not been filed or declared effective by the Commission, as applicable, or on the date after the Effectiveness Date and prior to the End Date that an effective Resale Registration Statement becomes unavailable
(each such date in clauses (i)-(iii) being referred to herein as an “Event Date”) and on each monthly anniversary of such Event Date until the later of the
date the Resale Registration Statement is filed or declared effective or available, as appliable, or the End Date, the Company shall pay to the Advisor an amount in cash, as partial or liquidated damages and not as a penalty, equal to the product of
7.5% multiplied by the aggregate value of the unsold Shares based on the closing price of the ADSs on the Trading Day prior to the date the Shares are issued to the Advisor; provided that the aggregate amount of liquidated damages payable hereunder
shall not exceed 50% multiplied by the aggregate value of the unsold Shares based on the VWAP at the time of issuance to the Advisor. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after
the date payable, the Company will pay interest thereon at a rate of 12% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Advisor, accruing daily from the date such partial liquidated damages are due
until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the Resale Registration Statement being
filed, declared effective or made available again, as the case may be.
For so long as the Advisor holds the Shares, the Advisor shall not, on any single Trading Day, sell a number of ADSs constituting more
than 20% of the trading volume of the ADSs on such Trading Day; provided, however,
in the event that on an given Trading Day (a) VWAP exceeds US$2.00 (subject to adjustment for reverse stock splits and the like) and (b) the average daily dollar trading volume of the ADSs for the 30 days prior to such Trading Day is greater than
US$350,000, Advisor shall be permitted to sell up to 50% of the trading volume of the ADSs sold such Trading Day.
5. Disclaimer of Responsibility for Acts of the Company. The obligations of Advisor described in this Agreement consist solely of providing Financial Services to
the Company. In no event shall Advisor be required by this Agreement to act as the agent of the Company or otherwise to represent or make decisions for the Company. The Company hereby acknowledges that Advisor is not a fiduciary of the Company.
All final decisions with respect to acts of the Company or its affiliates, whether or not made pursuant to or in reliance upon information or advice furnished by Advisor hereunder, shall be those of the Company or such affiliates, and Advisor shall
under no circumstances be liable for any expense incurred or loss suffered by the Company as a consequence of such decisions.
6. Confidentiality. Solely for use in connection with Advisor’s activities on behalf of the Company, the Company will furnish Advisor with all financial and other
information regarding the Company that Advisor reasonably believes appropriate in connection with providing the Financial Services (all such information so furnished by the Company, whether furnished before or after the date of this Agreement,
being referred to herein as the “Information”). Advisor shall at all times maintain the confidentiality of the Information and, unless and until such
information shall have been made publicly available by the Company or by others without breach of a confidentiality agreement or other duty to keep such Information confidential, shall disclose the Information only as authorized by the Company in
writing or as required by law or by order of a governmental authority or court of competent jurisdiction. In the event that Advisor is legally required to make disclosure of any of the Information, Advisor will give prompt notice to the Company
prior to such disclosure, to the extent that Advisor can practically do so without violating any applicable law.
7. Amendment. No amendment to this Agreement shall be valid unless such amendment is in writing and is signed by authorized representatives of all the parties to
this Agreement.
8. Waiver. Any of the terms and conditions of this Agreement may be waived at any time and from time to time in writing by the party entitled to the benefit
thereof, but a waiver in one instance shall not be deemed to constitute a waiver in any other instance. A failure to enforce any provision of this Agreement shall not operate as a waiver of this provision or of any other provision hereof.
9. Severability. In the event that any provision of this Agreement shall be held to be invalid, illegal, or unenforceable in any circumstances, the remaining
provisions shall nevertheless remain in full force and effect and shall be construed as if the unenforceable portion or portions were deleted.
10. Assignment. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. Any attempt by
either party to assign any rights, duties, or obligations which may arise under this Agreement without the prior written consent of the other party shall be void.
11. Governing Law and Arbitration. The validity, interpretation and construction of this Agreement and each part thereof will be governed by the laws of the State
of New York, without giving effect to its conflict of law principles or rules.
12. Counterparts. This Agreement may be executed in any number of counterparts, each of which may be deemed an original and all of which together will constitute
one and the same instrument.
13. Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the Financial Services, and neither party is relying on any
agreement, representation, warranty, or other understanding not expressly stated herein with respect to the Financial Services.
Indemnification and Contribution
As a material part of the consideration for the agreement of Advisor to furnish its services under the Agreement, the Company agrees to
indemnify and hold harmless Advisor and its affiliates, and their respective directors, officers, employees, agents, and controlling persons within the meaning of either Section 15 of the Securities Act of 1933, as amended (15 USC §770), or Section
20 of the Securities Exchange Act of 1934, as amended (15 USC §78t) (collectively, the “Indemnified Parties”), to the fullest extent lawful, from and against any and all losses, claims, damages, or liabilities (or actions in respect thereof), joint
or several, arising out of or related to the Agreement, any actions taken or omitted to be taken by an Indemnified Party in connection with the Agreement. In addition, the Company agrees to reimburse the Indemnified Parties for any legal or other
expenses reasonably incurred by them in respect thereof at the time such expenses are incurred. Notwithstanding the foregoing, the Company shall not be liable under the foregoing indemnity and reimbursement agreement for any loss, claim, damage, or
liability that is finally judicially determined to have resulted primarily from the fraud, willful misconduct or gross negligence of any Indemnified Party.
If for any reason the foregoing indemnification is unavailable to any Indemnified Party or is insufficient to hold it harmless (other
than pursuant to the exceptions listed above), the Company shall contribute to the amount paid or payable by the Indemnified Party in such proportion as is appropriate to reflect the relative benefits received (or anticipated to be received) by the
Company, on the one hand, and Advisor , on the other hand, in connection with the services rendered by Advisor. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law or otherwise, then the
Company shall contribute to such amount paid or payable by any Indemnified Party in such proportion as is appropriate to reflect not only such relative benefits, but also the relative fault of the Company, on the one hand, and Advisor, on the other
hand, in connection therewith, as well as any other relevant equitable considerations. Notwithstanding the foregoing, the aggregate contribution of all Indemnified Parties to any such losses, claims, damages, liabilities, and expenses shall not
exceed the amount of compensation actually received by Advisor under the Agreement.
The Company shall not effect any settlement or release from liability in connection with any third party claim for which an Indemnified
Party would be entitled to indemnification from the Company, unless such settlement or release contains a release of the Indemnified Parties reasonably satisfactory in form and substance to Advisor (with such approval not to be unreasonably withheld
or delayed) and does not include any admission of fault on the part of any Indemnified Person. The Company shall not be required to indemnify any Indemnified Party for any amount paid or payable by such party in the settlement or compromise of any
claim or action without the Company’s prior written consent.
|
|
CRAIG-HALLUM
CAPITAL GROUP LLC
By:
/s/ Rick Hartfiel
Name: Rick Hartfiel
Title: Head of Investment Banking
|
ACCEPTED & AGREED TO:
TRINITY BIOTECH PLC
By: /s/ John Gillard
Name: John Gillard
Title: CEO